Our results have demonstrated functional competition between SEMA3B and VEGF for NRP1 binding, thereby suppressing the activation of the VEGF signaling pathway and ultimately inhibiting tumor angiogenesis. This evidence concerns the gene SEMA3B and neoplasm.